The US Congress signs legislation aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs

On April 23, 2021, President Biden signed into law two bipartisan bills aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs. The Ensuring Innovation Act supports generic drugs by clarifying the technical qualifications for earning exclusivity as a "new chemical entity." The Advancing Education on Biosimilars Act provides for increased federal efforts to educate patients, doctors and caregivers about biosimilar drugs. These changes come as proposals for more comprehensive legislation on drug pricing, such as allowing Medicare to negotiate prices directly with manufacturers, have thus far been excluded from the Biden Administration’s major spending initiatives. Below is a short summary of each new bill. The Ensuring

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • White & Case (New York)
  • White & Case (New York)

Quotation

Michael Gallagher, Kevin Adam, The US Congress signs legislation aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs, 23 April 2021, e-Competitions April 2021, Art. N° 100819

Visites 170

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues